Theriva Biologics, Inc. (TOVX) Q2 2023 Earnings Call

Investor webinar replay

Replay transcript excerpt

Ladies and gentlemen, good morning and welcome to the Tergiva Biologics, Inc. 2023 Second Quarter Earnings Conference Call. At this time, all participants are in a listen-only mode. A brief question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star and zero on your telephone keypad. As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Chris Calabrese from Lifesave Advisors. Please go ahead. Thank you, Operator, and good morning, everyone. Welcome to Theriva Biologics' second quarter of 2023 investor conference call. Leading the call today will be Stephen Shawcross, Chief Executive and Chief Financial Officer of Theriva Biologics, Dr. Manel Cascaio, General Director of Theriva Biologics European Subsidiary, and Dr. Vince Wacher, Head of Corporate and Product Development of Cereva Biologics, are also on the call and will be available to answer questions during the Q&A session. Cereva Biologics issued a press release this morning, which provided operational highlights and included the financial results for the second quarter ending June 30, 2023. The press release can be found in the Investors section of the company website at www.cerevabio.com. together with the quarterly report on Form 10-Q for the quarter ended June 30, 2023, which we plan to file today with the Securities and Exchange Commission, or SEC. In addition to the phone line, this call is being streamed live via webcast, which will be archived on the company website, www.therivabio.com, for 90 days. During this call, certain forward-looking statements regarding Theriva Biologics and VCN biosciences, current expectations, and projections about future events will be made. Gene...